Philogen Logo

Philogen

Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.

PHIL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005373789 (+1 more)
LEI:
81560009EA1577917768
Country:
Italy
Address:
PIAZZA LA LIZZA, 7, 53100 SIENA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Philogen is a Swiss-Italian biotechnology company, founded in 1996, that develops innovative biopharmaceuticals for the treatment of cancer and other serious conditions. The company is a pioneer in proprietary ligand-based targeting approaches, which use high-affinity antibodies and small molecules to deliver therapeutic agents directly to the site of disease. As a fully-integrated company, its expertise spans from the discovery of novel tumor markers using chemical proteomics to the GMP manufacturing of its targeted therapies, such as immunocytokines and radioligand therapeutics. Philogen's clinical-stage pipeline focuses primarily on oncology indications.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 20:02
Regulatory News Service
The Board of Directors approves the financial position for the third quarter of…
Italian 292.6 KB
2025-11-11 20:01
Regulatory News Service
Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa…
Italian 295.3 KB
2025-11-10 12:39
Director's Dealing
Allegato 3F
Italian 26.5 KB
2025-10-13 13:36
Transaction in Own Shares
2025 10 13 - CS settimanale acquisto azioni proprie
Italian 295.3 KB
2025-10-06 18:50
Director's Dealing
Allegato 3F
Italian 26.9 KB
2025-10-06 18:15
Transaction in Own Shares
2025 10 06 - CS settimanale acquisto azioni proprie
Italian 294.0 KB
2025-09-29 17:58
Transaction in Own Shares
2025 09 29 - CS settimanale acquisto azioni proprie
Italian 298.0 KB
2025-09-26 12:26
Interim Report
Half Year Report 2025 as of 30.06.2025 (Courtesy English Translation)
English 2.1 MB
2025-09-26 12:24
Interim Report
Relazione Finanziaria Semestrale al 30.06.2025
Italian 2.0 MB
2025-09-23 21:11
Earnings Release
The Board of Directors Approves the Half-Yearly Financial Report at 30 June 202…
English 416.6 KB
2025-09-23 21:10
Interim Report
Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al …
Italian 377.0 KB
2025-09-15 14:52
Transaction in Own Shares
2025 09 15 - CS settimanale acquisto azioni proprie
Italian 184.3 KB
2025-08-18 20:02
M&A Activity
Press Release Clearance e Closing OncoACP3 (Price Sensitive)
Italian 213.9 KB
2025-07-07 16:50
Transaction in Own Shares
2025 07 07 - CS settimanale acquisto azioni proprie
Italian 153.0 KB
2025-07-07 12:08
Director's Dealing
Allegato 3F
Italian 26.7 KB

Automate Your Workflow. Get a real-time feed of all Philogen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Philogen

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Philogen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.